KT032

KT032 is an **autologous CAR-T cell therapy** targeting **mesothelin (MSLN)**, developed for the treatment of mesothelin-expressing advanced solid tumors. KT032 utilizes genetically engineered autologous T cells designed to recognize and kill cells expressing mesothelin, a protein overexpressed in certain cancers such as ovarian cancer, mesothelioma, and pancreatic cancer. The drug is in early clinical development and is being investigated for safety and anti-tumor efficacy. The therapy is developed by Nanjing Kati Medical Technology and represents an immunotherapy approach, harnessing the cytotoxic potential of T cells redirected against tumor antigens via a chimeric antigen receptor targeting mesothelin.